Featured Posts
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…
National Review
Telehealth Is Less Promising Than It First Seemed
A key issue facing Congress in its postelection, “lame duck” session is whether to extend regulatory flexibilities expiring at year end that make telehealth services more…
Search Posts
Real Clear Markets
Global Governments’ Growing Embrace of Big Pharma
As the pharmaceutical industry wrestles with multiple existential threats-from price controls to patent cliffs to dwindling pipelines-calls are growing for deeper government-industry cooperation. As private…
Washington Times
High Price of Cheap Drug Imports
With the Senate set to vote on one of the few “must-pass” bills of the year, pharmaceutical industry critics are plotting ways to add poison…
Washington Times
ObamaCare’s Killer Device Tax
Much of the political conversation in Washington these days concerns innovation, job creation and competitiveness. But talk is cheap, and elected officials must enact policies…
Washington Times
The Off-Label Drug War of Words
If knowledge is power and ignorance is bliss, what is power used to prevent knowledge from eliminating ignorance? I don’t know; ask the FDA (U.S.
Heartlander
Critical Drug Shortages Reaching Crisis
From Ashley Bateman's article on Heartland.org: But according to Greg Conko, a senior fellow at the Competitive Enterprise Institute, more mandates on companies…
Medical Progress Today
Mayo v. Prometheus and Diagnostic Patents: What Does the Supreme Court Decision Really Mean?
I finally had a chance to read the Supreme Court's recent decision in the Mayo v. Prometheus Labs case, which invalided two patents claiming methods…